Penny stocks are very convenient for those who don’t have a big capital for investments, to begin with. They are affordable for a low price, as usual, under $5 per share. But investors must choose carefully, because some of those stocks can’t top their initial value, thus bringing no serious gain to shareholders. Mostly the reason is bad management, weak fundamentals, irrelevant equipment, etc.
On the other hand, some of them surge towards record highs, bringing hefty profit. The analysts recommend several penny stocks, which have the potential to end 2020 in the green.
Here are the Three “Strong-Buy” Penny Stocks:
TETRA Technologies’ current price tag is $1.51 per share. This company provides the upstream energy industry with solutions for water management and completion fluids. It also offers various compression services.
Though TETRA met several difficulties during 2019, this stock still has a lot going for it. Tom Curran from B.Riley FBR thinks a 132% twelve-month gain could be in store. But he reduced the price target from $3.75 to $3.50.
Matinas BioPharma Holdings is another profitable penny stock. It plans to offer new treatments for cardiovascular and metabolic conditions. The company is devising new medicine, which will be a highly effective hypertriglyceridemia treatment.
Gregg Gilbert, SunTrust Robinson analyst, thinks now is an excellent time to buy this stock. The present price is $1.35 per share. He believes the new drug, MAT9001, could cut out a nice slice of the omega-3 market. Gilbert set the price target at $3, in which case shares could be in for a 122% gain over the next twelve months.
Marrone Bio Innovations is presently trading for $1.14 per share. Some experts think this price can increase. The company uses microorganisms isolated from samples collected from flowers, soil insects, and composts to find effective solutions for plant health and pest management. It grew by 46% in the first three quarters of 2019.
Even though the stock had some drawbacks, it managed to overcome obstacles. National Securities analyst Ben Klieve set its price target at $2.50, with 119% potential gain in the next twelve months.
(TTI) (MTNB) (MBII)
